What Is Cardiogen?

First, Cardiogen is a synthetic tetrapeptide composed of alanine, glutamic acid, aspartic acid, and arginine. Its sequence is Ala–Glu–Asp–Arg, abbreviated AEDR.

Next, it is commonly classified within Khavinson-school literature as a heart-associated or myocardial peptide bioregulator. Published work has examined proliferation in myocardial tissue explants, p53 expression, apoptosis-related interpretations, age-dependent tissue responses, and effects in an experimental rat tumor model.

🧬 Molecular Structure

First, Cardiogen is a linear tetrapeptide composed of L-alanine, L-glutamic acid, L-aspartic acid, and L-arginine. The standard research form is generally represented with a free N-terminus and free C-terminal carboxyl group.

🧪 Amino-Acid Sequence

H-Ala-Glu-Asp-Arg-OH

One-letter notation: AEDR

⚛️ Molecular Weight and 🧫 Formula

Importantly, sequence permutations containing A, E, D, and R share the same elemental composition and nominal mass. Exact sequence order requires tandem mass spectrometry or another orthogonal sequence method.

📅 Discovery Timeline and Research History

1970s–1990s: Organ-specific peptide research develops

First, Russian and Eastern European researchers studied low-molecular-weight peptide fractions from heart, vessels, liver, thymus, pineal gland, and other tissues.

1990s–2000s: Defined cardiac tetrapeptide synthesized

Next, researchers developed AEDR as a chemically defined candidate heart-associated peptide bioregulator.

2002: General peptide-aging framework

Moreover, a review described tissue-associated tetrapeptides, including a heart-specific tetrapeptide, as stimulating explant growth in corresponding tissues.

2009: Myocardial-tissue and p53 study

In addition, Cardiogen increased explant growth in young and old rat myocardial tissue and reduced p53 protein expression by immunohistochemistry.

2009: Rat M-1 sarcoma study

Likewise, Cardiogen increased apoptosis and hemorrhagic necrosis in an experimental transplanted tumor model and inhibited tumor growth in a dose-dependent manner.

2021–2022: Systematic peptide reviews

Meanwhile, broader reviews discussed short peptides as regulators of proliferation, apoptosis, differentiation, gene expression, and cellular transport.

Current status

Finally, Cardiogen remains unapproved. No large modern program has established clinical efficacy in myocardial infarction, heart failure, cardiomyopathy, fibrosis, or cardiovascular aging.

Cardiac Physiology and Remodeling

Cardiomyocytes

First, cardiomyocytes generate force through coordinated calcium handling, sarcomere contraction, mitochondrial ATP production, and electrical coupling. Adult mammalian cardiomyocytes have limited proliferative capacity.

Cardiac fibroblasts

Next, fibroblasts maintain extracellular matrix and become activated after injury. They produce collagen and other matrix proteins that stabilize damaged tissue but can cause pathological stiffness when activation becomes excessive.

Myocardial infarction

Moreover, loss of blood flow causes cardiomyocyte death, inflammation, scar formation, ventricular remodeling, and possible heart failure.

Pressure overload

In addition, hypertension and valve disease can cause hypertrophy, fibroblast activation, extracellular-matrix accumulation, chamber remodeling, and declining function.

p53 in the heart

Finally, p53 influences apoptosis, cell-cycle arrest, metabolism, angiogenesis, and stress responses. Its role is context dependent: excessive activation can contribute to cardiomyocyte death, while suppression can permit genomic instability or abnormal proliferation.

🧠 Proposed Mechanisms of Action

Importantly, researchers have not established a validated high-affinity receptor or single molecular mechanism for Cardiogen.

1. Proliferation signaling

First, Cardiogen increased the growth area of rat myocardial explants. The specific responding cell population was not conclusively shown to be mature cardiomyocytes.

2. p53-associated apoptosis

Next, reduced p53 immunostaining was interpreted as possible inhibition of apoptosis in myocardial tissue. Direct measurements of downstream apoptosis pathways were limited.

3. Gene-expression hypothesis

Moreover, broader ultrashort-peptide literature proposes direct or indirect regulation of gene expression, protein synthesis, or chromatin state. AEDR-specific genomic targets are not well established.

4. DNA-hydrolysis and enzyme-interaction hypotheses

However, commercial summaries sometimes describe Cardiogen as influencing endonuclease-mediated DNA hydrolysis. Strong independent primary evidence and clinical relevance remain unclear.

5. Tissue selectivity

Finally, no confirmed receptor, transporter, or targeting sequence proves preferential delivery of AEDR to cardiomyocytes or cardiac fibroblasts.

🎯 Target and Pathway Profile

Myocardial Proliferation and p53 Research

Rat myocardial explant model

First, a 2009 study evaluated amino acids and Cardiogen in myocardial tissue from young and old rats. Cardiogen produced the largest stimulation of explant proliferation among the tested conditions.

What “proliferation” means here

Next, explant growth can reflect migration or proliferation of fibroblasts, endothelial cells, progenitor-like cells, or other stromal populations. It does not automatically demonstrate division of mature cardiomyocytes.

p53 reduction

Moreover, immunohistochemistry showed lower p53 protein expression after Cardiogen exposure. Investigators interpreted this as possible suppression of apoptosis.

Why lower p53 is not automatically beneficial

However, p53 protects against DNA-damaged cell survival and tumor formation. Long-term or excessive suppression could theoretically increase oncogenic risk or permit maladaptive growth.

No functional cardiac endpoints

Finally, the study did not establish improved ejection fraction, exercise tolerance, electrical conduction, infarct size, hospitalization, or survival.

Fibrosis and Remodeling Claims

Direct Evidence Remains Limited

First, commercial summaries often state that Cardiogen inhibits fibroblast growth and reduces scar formation. The direct primary Cardiogen literature identified for this review does not robustly establish that conclusion.

Fibroblasts can be beneficial or harmful

Next, after myocardial infarction, fibroblast activation is essential for scar stability. Excessive suppression can increase rupture risk, while excessive matrix production can worsen stiffness and heart failure.

p53 and fibrosis are context dependent

Moreover, modern cardiac-fibrosis research shows that p53-dependent cell-cycle control helps regulate fibroblast accumulation and extracellular-matrix secretion. Cardiogen’s reduction of p53 in one tissue model cannot be assumed to produce an antifibrotic effect.

Needed studies

In addition, valid fibrosis claims would require measurements of collagen deposition, fibroblast activation, matrix metalloproteinases, scar thickness, ventricular geometry, compliance, and cardiac function in well-controlled injury models.

No proof of post-infarction remodeling benefit

However, no robust modern study establishes that Cardiogen improves scar quality or prevents adverse ventricular remodeling after myocardial infarction.

Oxidative Stress, Ischemia, and Mitochondrial Claims

Common commercial claims

First, Cardiogen is frequently described as supporting mitochondrial resilience, reducing oxidative stress, and protecting the myocardium during hypoxia.

Direct evidence gap

However, these claims are biologically plausible research questions but are not strongly established by the core Cardiogen studies identified.

Relevant endpoints

Moreover, appropriate research would measure mitochondrial respiration, ATP production, membrane potential, reactive oxygen species, lipid oxidation, calcium overload, mitophagy, apoptosis, and infarct size.

Ischemia-reperfusion complexity

In addition, cardiac ischemia-reperfusion injury involves oxidative stress, calcium dysregulation, mitochondrial permeability transition, inflammation, necrosis, apoptosis, pyroptosis, and microvascular injury.

No replacement for cardiovascular treatment

Finally, Cardiogen cannot substitute for reperfusion, antiplatelet therapy, statins, beta blockers, ACE inhibitors, ARBs, mineralocorticoid antagonists, SGLT2 inhibitors, or other evidence-based treatments when indicated.

Tumor-Model Research

M-1 sarcoma study

First, in rats with transplanted M-1 sarcoma, Cardiogen increased tumor-cell apoptosis and hemorrhagic necrosis and inhibited tumor growth in a dose-dependent manner.

Different effect from myocardial tissue

However, the tumor study reported increased apoptosis, while the myocardial study interpreted lower p53 as reduced apoptosis. This suggests strong context dependence rather than one universal mechanism.

No established anticancer therapy

Moreover, a single transplanted-tumor model does not establish efficacy against human cancer, metastasis, recurrence, or treatment resistance.

Possible safety implications

Finally, opposing effects on proliferation and apoptosis across tissues make comprehensive toxicology and oncologic assessment especially important.

Evidence Limitations and Clinical Interpretation

Small evidence base

First, only a small number of preclinical studies and reviews provide direct Cardiogen evidence.

Limited independent replication

Next, many findings originate from related investigators and institutions.

No modern human heart-failure trials

Moreover, no large randomized study demonstrates improved ejection fraction, symptoms, hospitalization, cardiovascular events, or mortality.

No established fibrosis outcome

In addition, claims of scar reduction or antifibrotic activity remain insufficiently supported.

No established cardiomyocyte regeneration

Likewise, explant growth does not prove production of mature, electrically integrated, force-generating cardiomyocytes.

No approved formulation or dosing

Finally, there is no FDA-approved route, dose, duration, monitoring plan, or interaction guidance.

Safety and Regulatory Considerations

No standardized human safety profile

First, no FDA-approved prescribing information defines pharmacokinetics, contraindications, interactions, pregnancy safety, or long-term adverse effects.

p53 suppression concern

Moreover, suppressing p53 may reduce apoptosis in stressed cells but could also permit survival of damaged cells and increase tumor risk.

Proliferation concern

In addition, any compound increasing tissue growth requires evaluation for fibrosis, hypertrophy, neoplasia, arrhythmogenic remodeling, and inappropriate vascular proliferation.

Cardiovascular interaction uncertainty

Likewise, potential interactions with anticoagulants, antiplatelet drugs, blood-pressure medicines, antiarrhythmics, and heart-failure therapies are unknown.

Product-quality risk

However, unapproved products may contain the wrong sequence, sequence isomers, residual solvents, microbial contamination, endotoxin, or inaccurate peptide content.

Regulatory status

Finally, Cardiogen/AEDR is not FDA approved as a drug or biologic. It should not be confused with CardioGen-82, an unrelated rubidium-82 generator used for cardiac PET imaging.

🧪 Laboratory Testing Methods

Identity, Sequence, and Stability Testing

📄 How to Interpret a Cardiogen COA

COA Review and Route-Specific Quality

1. Therefore, Verify the exact sequence: H-Ala-Glu-Asp-Arg-OH or AEDR.
2. For example, Confirm sequence order: Molecular mass alone cannot distinguish AEDR from sequence isomers.
3. Meanwhile, Verify stereochemistry: Expected research material generally uses L-amino acids.
4. Likewise, Check terminal form and counterions: Acetylated, amidated, or salt forms are different materials.
5. In addition, Separate identity, purity, and net content: These are different analytical measurements.
6. Moreover, Review sequence isomers, pyroglutamate, isoaspartate, free amino acids, water, and residual solvents.
7. By contrast, Match testing to the intended route: Raw-powder purity does not establish injectable or oral suitability.
8. Also, Do not infer cardiac efficacy: A COA cannot prove myocardial repair, antifibrotic activity, improved ejection fraction, mitochondrial protection, or cardiovascular safety.

📊 Cardiogen vs Vesugen vs Bronchogen vs Epitalon

Sequence and Cardiac-Research Differences

Cardiogen vs BPC-157 vs TB-4

Ultrashort Cardiac Peptide Versus Broader Repair Peptides

Cardiogen vs Evidence-Based Heart-Failure Therapy

🔗 Related Peptides and Cardiac Pathways

• Vesugen: First, KED tripeptide associated with vascular-endothelial research.
• Bronchogen: Next, AEDL tetrapeptide associated with respiratory tissue.
• Epitalon: Also, AEDG tetrapeptide associated with pineal and aging research.
• p53: Moreover, Stress-response protein involved in apoptosis, cell-cycle control, metabolism, and fibrosis.
• Cardiac fibroblasts: In addition, Matrix-producing cells central to scar formation and remodeling.
• Cardiomyocytes: Likewise, Contractile heart-muscle cells with limited adult proliferative capacity.
• CardioGen-82: Finally, Unrelated FDA-regulated rubidium-82 generator for PET imaging.

🖼️ Original Diagram Specifications

Diagram 1: Cardiogen molecular structure

Likewise, Show H-Ala-Glu-Asp-Arg-OH with alanine’s methyl group, two acidic side chains, arginine’s guanidinium group, peptide bonds, and free termini.

Diagram 2: Myocardial explant experiment

In addition, Compare untreated young and old rat myocardial explants with Cardiogen-treated tissue, showing increased growth area without labeling it as proven cardiomyocyte regeneration.

Diagram 3: p53 pathway

Moreover, Show DNA damage, p53 activation, cell-cycle arrest, apoptosis, repair, and the reported reduction in p53 staining after Cardiogen exposure.

Diagram 4: Cardiac remodeling

By contrast, Show cardiomyocyte injury, inflammation, fibroblast activation, collagen scar, hypertrophy, dilation, and heart failure. Mark Cardiogen’s antifibrotic effects as unconfirmed.

Diagram 5: Myocardial tissue vs tumor model

Also, Contrast reduced p53/apoptosis interpretation in myocardial tissue with increased apoptosis and necrosis in M-1 sarcoma.

Diagram 6: Evidence ladder

Consequently, Show chemistry, tissue explants, p53 immunostaining, animal tumor model, cardiac injury models, controlled human trials, and FDA approval. Place Cardiogen below confirmatory cardiac evidence.

Diagram 7: COA workflow

However, Show exact mass, MS/MS sequence, stereochemistry, sequence isomers, pyroglutamate, isoaspartate, net content, residuals, microbiology, and stability.

❓ Frequently Asked Questions

Is Cardiogen a peptide?

Therefore, Yes. It is a synthetic tetrapeptide.

What is the correct sequence?

H-Ala-Glu-Asp-Arg-OH, abbreviated AEDR.

What is its molecular weight?

For example, Approximately 489.49 g/mol for neutral AEDR.

Is Cardiogen FDA approved?

No.

Does Cardiogen regenerate heart muscle?

Meanwhile, No. Rat myocardial explants showed increased growth, but mature functional cardiomyocyte regeneration was not established.

Does it reduce p53?

Likewise, A myocardial-tissue study reported reduced p53 immunostaining after Cardiogen exposure.

Does lower p53 always protect the heart?

In addition, No. p53 has both protective and harmful roles depending on stress, cell type, and disease stage.

Does Cardiogen reduce cardiac fibrosis?

Moreover, Direct Cardiogen-specific antifibrotic evidence is insufficient.

Does it protect mitochondria?

By contrast, This is a common hypothesis, but strong direct Cardiogen mitochondrial evidence is lacking.

Does Cardiogen treat heart failure?

Also, No approved indication or large clinical trial supports that use.

Is Cardiogen anticancer?

Consequently, One rat sarcoma model showed increased apoptosis and reduced tumor growth, but this does not establish human cancer treatment.

Is Cardiogen the same as CardioGen-82?

However, No. CardioGen-82 is an unrelated rubidium-82 generator used for PET myocardial-perfusion imaging.

Does 99% HPLC purity prove cardiac activity?

Therefore, No. Sequence, stereochemistry, net content, functional potency, pharmacokinetics, safety, and clinical outcomes must be established separately.

Cardiogen Scientific Overview: Final Thoughts

In conclusion, Cardiogen is a defined tetrapeptide with the sequence Ala–Glu–Asp–Arg. Its strongest direct cardiac research involves increased growth of young and old rat myocardial explants and reduced p53 protein expression.

However, those findings are mechanistically interesting but do not establish cardiomyocyte regeneration, antifibrotic activity, mitochondrial protection, improved ventricular remodeling, or treatment of heart failure. A separate rat sarcoma study showed increased apoptosis and tumor necrosis, emphasizing that Cardiogen’s effects may vary substantially by tissue.

Therefore, analysts should verify legitimate research material for exact AEDR sequence order, L-amino-acid stereochemistry, terminal chemistry, sequence isomers, pyroglutamate, isoaspartate, free amino acids, net peptide content, route-specific microbiological quality, and stability.

📚 References

Cardiogen, Myocardial, and Tumor-Model Sources

1. For example, Chalisova NI, et al. The effect of amino acids and Cardiogen on cell proliferation and p53 expression in myocardial tissue. 2009.
2. Meanwhile, Levdik NV, et al. Tumor-modifying effect of Cardiogen peptide on M-1 sarcoma. 2009.
3. Likewise, Khavinson VK. Peptides and ageing. Neuro Endocrinology Letters. 2002.
4. In addition, Khavinson V, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021.
5. Moreover, Khavinson V, et al. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. 2022.
6. By contrast, Avolio F, et al. Peptides Regulating Proliferative Activity and Inflammatory Pathways. 2022.
7. Also, Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010.
8. Consequently, Khavinson VK, Kuznik BI. Peptide Bioregulators: The New Class of Geroprotectors. 2014.
9. However, Solovyev AY, et al. Interaction of amino acids, peptides, and proteins with DNA. 2015.
10. Therefore, Daniel H. Molecular and integrative physiology of intestinal peptide transport. Annual Review of Physiology.
11. For example, Brandsch M. Drug transport via the intestinal peptide transporter PepT1. Current Opinion in Pharmacology.
12. Meanwhile, Smith DE, Clémençon B, Hediger MA. Proton-coupled oligopeptide transporter family SLC15. Molecular Aspects of Medicine.
13. Likewise, Newstead S. Molecular insights into proton-coupled peptide transport. Trends in Pharmacological Sciences.
14. In addition, Men H, et al. The regulatory roles of p53 in cardiovascular health and disease.
15. Moreover, Long X, et al. p53 and hypoxia-induced apoptosis of cultured neonatal rat cardiac myocytes. 1997.
16. By contrast, Song H, et al. Increased p53 protein expression in human failing myocardium. 1999.
17. Also, Liu X, et al. p53 regulates the extent of fibroblast proliferation and cardiac fibrosis. 2023.
18. Consequently, Garbern JC, et al. p53-induced quiescence and maturation of human iPSC-derived cardiomyocytes. Circulation. 2020.

Cardiac Biology, Fibrosis, and Analytical Sources

19. However, Frangogiannis NG. Cardiac fibrosis. Cardiovascular Research.
20. Therefore, Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodeling. Nature Reviews Cardiology.
21. Likewise, Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac fibrosis: the fibroblast awakens. Circulation Research.
22. For example, Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction. Circulation Research.
23. Moreover, Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction—from repair and remodeling to regeneration. Cell and Tissue Research.
24. In addition, Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection. Nature Reviews Cardiology.
25. However, Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. Journal of Clinical Investigation.
26. Therefore, Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiological Reviews.
27. Likewise, Li Y, et al. Mitochondrial-derived peptides in cardiovascular disease. 2023.
28. For example, Boshchenko AA, et al. Peptides are cardioprotective drugs of the future. 2024.
29. Moreover, Yao Y, et al. Multifunctional cardiac patches for preventing adverse remodeling after myocardial infarction. 2022.
30. In addition, McDonagh TA, et al. ESC guidelines for diagnosis and treatment of acute and chronic heart failure.
31. However, Heidenreich PA, et al. AHA/ACC/HFSA guideline for the management of heart failure.
32. Therefore, Virani SS, et al. AHA/ACC guideline for chronic coronary disease.
33. Likewise, International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures.
34. For example, United States Pharmacopeia. General Chapter <621>, Chromatography.
35. Moreover, United States Pharmacopeia. General Chapters <61> and <62>, Microbiological Examination of Nonsterile Products.
36. United States Pharmacopeia. General Chapter <71>, Sterility Tests.
37. United States Pharmacopeia. General Chapter <85>, Bacterial Endotoxins Test.
38. United States Pharmacopeia. General Chapters <232> and <233>, Elemental Impurities.
39. International Council for Harmonisation. ICH Q3C: Impurities—Guideline for Residual Solvents.
40. International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products.

Identity, molecular properties, myocardial proliferation, p53, fibrosis, tumor-model, safety, and regulatory findings were reviewed in July 2026. Cardiogen remains an unapproved research peptide.